Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

20 May 2023 (08:00 - 20:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor John Ostrominski

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail

Maximal functional capacity response to physical therapies according to ferrokinetics in heart failure with preserved ejection fraction. A substudy of the training-hf trial

Doctor P. Palau Sampio (Valencia, ES)

Abstract Slides

Presentation thumbnail

A ventricular conduction delay phenotype and its outcome in heart failure with preserved ejection fraction

Ms A. Achten (Maastricht, NL)

Abstract Slides

Presentation thumbnail

Invasive validation of H2FPEF score for diagnosis of heart failure with preserved ejection fraction (HFpEF)

Doctor M. Podolec (Prague, CZ)

Abstract Slides

Presentation thumbnail

Retinal neurovascular changes in heart failure with preserved ejection fraction: an optical coherence tomography angiography pilot study

Mr J. Weerts (Maastricht, NL)

Abstract Slides

Access the full session

Session thumbnail

Heart failure with preserved ejection fraction (HFpEF) 3

The Event

Event poster

Heart Failure 2023

20 May - 23 May 2023

You may be interested in

Congress Presentation

Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.

Congress Presentation

Pharmacotherapy in HFpEF: where do cardiometabolic drugs fit in?

Congress Session

Clinical phenotypes of heart failure with preserved ejection fraction

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources